Differences in the inflammatory activity of certain immune cells may explain why amyotrophic lateral sclerosis (ALS) progresses faster in some people than others, according to a study. The findings suggest that it may be possible to slow ALS progression by targeting specific inflammatory disease markers. “The intensity of spinal…
News
Neurizon Therapeutics has received ethics approval for an Australia-based Phase 1 clinical trial that will test an oral liquid formulation of NUZ-001, which the company is developing for amyotrophic lateral sclerosis (ALS), in healthy volunteers. A tablet version of NUZ-001 is being tested in a Phase 2/3 clinical…
An international team of scientists has developed an RNA-based experimental medicine that has the potential to reduce clumping of the TDP-43 protein, a key molecular feature of amyotrophic lateral sclerosis (ALS). The researchers determined, in precise molecular detail, how the RNA-based therapy interacts with the TDP-43 protein and showed…
Dutch Bros is holding its annual Drink One for Dane Day of Giving fundraiser this Friday, May 15, with the Dutch Bros Foundation and franchisees donating $1 from every drink sold to support the fight against amyotrophic lateral sclerosis (ALS). The event raises funds and awareness of…
COYA 302, Coya Therapeutics’ investigational therapy for amyotrophic lateral sclerosis (ALS) — shown in an early clinical trial to slow disease progression in a small number of patients — has been awarded fast track status by the U.S. Food and Drug Administration (FDA). That designation is intended to…
The ALS Association has awarded $3 million to help expand access to specialized amyotrophic lateral sclerosis (ALS) care in underserved and geographically isolated communities across the U.S. The funding comes from the organization’s Hoffman ALS Clinic Development and Capacity Awards programs, established through a historic $58 million…
A cellular recycling system that degrades damaged or unwanted proteins is impaired in motor neurons from people with amyotrophic lateral sclerosis (ALS), suggesting it could be a target for future therapies aimed at slowing disease progression, according to a new study. The research also showed that motor neurons in…
EverythingALS has launched a new online tool called SAVA AI that uses artificial intelligence to instantly match people with amyotrophic lateral sclerosis (ALS) to clinical trials. The platform is available for free through the EverythingALS website or as a mobile app, providing patients with a secure way…
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to tazbentetol, an experimental oral therapy being developed by Spinogenix for amyotrophic lateral sclerosis (ALS). Fast-track status is intended to speed the development and review of treatments for serious conditions with unmet medical needs. It will allow Spinogenix…
Acurastem has received $7.5 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance AS-241, its lead clinical candidate for amyotrophic lateral sclerosis (ALS) and related diseases, toward clinical trials. The grant was supported by cell-based studies showing that AS-241 can restore certain ALS-related defects…
Recent Posts
- Adult children of parents with ALS may need more support, study finds
- A funny thing happened on the way to the ALS forums
- Motor neuron diseases are on the increase in Europe, study finds
- Masitinib linked to higher 5-year survival rate in ALS trial
- Neurosense, Health Canada discuss approval path for PrimeC